Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive News from MarketBeat
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusAuthor: Jessica Mitacek. Posted: 5/8/2026. 
Key Points
- Following a settled legal dispute with Novo Nordisk, HIMS has transitioned from selling compounded weight-loss drugs to offering brand-name Wegovy and Ozempic.
- While the deal was finalized in March, investors are eager to see if this pivot will boost the top line or if the financial impact likely won’t be seen until Q2.
- Despite its recent rally, the stock remains highly volatile with short interest exceeding 35%.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
Healthcare stocks have struggled in 2026. With a year-to-date (YTD) loss of about 6%, the sector has been the worst performer among all 11 S&P 500 sectors this year. That weakness has been reflected in the YTD losses of some of Big Pharma’s biggest names, but it has also weighed on mid-cap stocks like telehealth platform Hims & Hers Health (NYSE: HIMS), which has fallen by more than 23% in 2026.
One day after a big announcement from the U.S. Food & Drug Administration (FDA) sent shares of HIMS up nearly 4%, the stock gave back those gains on Thursday, falling nearly 5% as traders locked in profits. Even so, that wasn’t enough to derail the stock’s recent rally, which has lifted HIMS nearly 32% over the past month and roughly 77% from its 52-week low on Feb. 27. As the company prepares to report Q1 2026 earnings on May 11, here’s what investors should watch for. Is the Novo Nordisk Partnership Already Paying Off?Following a well-publicized legal dispute earlier this year with Denmark-based Novo Nordisk (NYSE: NVO)—the world’s eighth-largest publicly traded pharmaceutical company, with a market cap of more than $204 billion—it has been smooth sailing for Hims & Hers. Since Novo Nordisk dropped its patent infringement lawsuit on March 9, HIMS has been on a tear. Not only did the Danish firm abandon its case, but it also reached a deal that allows Hims & Hers to sell Novo Nordisk’s brand-name Wegovy and Ozempic through its direct-to-consumer and virtual medical services platform. As part of that deal, Hims & Hers agreed to stop advertising its compounded GLP-1 products. That decision could prove prescient, given the FDA’s announcement that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from its 503B bulks list. Wall Street will be watching to see how the deal has affected Hims & Hers’ top line. Although the strategic shift was announced on March 9, Novo Nordisk’s GLP-1 products were not available for sale through the online platform until March 26. Since the first quarter closed on March 31, those gross sales may not show up on Hims & Hers’ income statement until Q2. Will Hims & Hers Continue to Show Subscriber Growth?The market will also be looking for confirmation that Hims & Hers’ total subscribers are holding above 2.5 million, if not continuing to grow from there. That benchmark was reached near the end of 2025 and marked a gain of more than 16% from the 2.2 million subscribers the company had at the end of 2024. That growth appears sustainable, after Hims & Hers ended 2023 with 1.5 million subscribers. But more important than the raw subscriber count is the way the telehealth company generates 90% of its recurring revenue from its customer base. Approximately 82% of its users remain on the platform for more than three months, and if Hims & Hers can show that retention remains strong, it should bolster full-year guidance. Meanwhile, analysts are expecting earnings per share (EPS) of around three to four cents, which would represent an estimated 90% year-over-year decline. That may already be priced in, given the stock’s YTD performance, but a miss could accelerate selling. The same goes for quarterly revenue, which consensus forecasts place in the range of $616 million to $619 million. Wall Street is already bracing for a “reset quarter” after revenue growth slowed from nearly 111% in Q1 2025 to less than 29% in Q4, so any upside surprise could spark another leg higher in the current rally. Analysts Are Taking a Wait-and-See ApproachDespite an average 12-month price target of nearly $32, which implies potential upside of around 24%, Wall Street remains cautious on the stock. Of the 17 analysts currently covering HIMS, four rate it a Buy, 12 rate it a Hold, and just one rates it a Sell. Overall, the stock carries a consensus Hold rating. Institutional ownership of nearly 64% falls within the typical range for mid-cap companies. Outflows of $1.62 billion have nearly caught up with inflows of $1.8 billion over the past 12 months, after selling accelerated in Q4 2025. But that trend reversed in Q1, with institutional selling 88% lower than institutional buying. With a high beta of 2.43, the stock is inherently volatile and is currently drawing heavy interest from bears. Concerningly, more than 35% of the float—or nearly 70 million shares of the almost 228 million shares outstanding—is currently shorted. Still, strong earnings could shift sentiment and move the stock closer to the consensus analyst price target. Shareholders and prospective investors should mark their calendars for Monday, May 11, when Hims & Hers Health reports Q1 2026 results. |
Post a Comment
0Comments